echothiophate iodide a convenient 24 hour solution to the 24 hour problem of tension control
long-acting...provides smooth control of intraocular pressure in the critical "nighttime" hours for the patient with chronic simple (open-angle) or aphakic glaucoma k flattens intraocular pressure curves to provide smoother, more consistent tension control "In this series [clinical trial involving 52 eyes of 41 glaucoma patients], echothiophate [PHOS- PHOLINE IODIDE], with one exception, appeared to eliminate large fluctuations in intraocular pressure, an effect probably related to its long duration of action."* It provides consistently lower pressures than pilocarpine.* minimizes the risk of forgotten doses Since patients are much more likely to adhere strictly to directions with a medication that need be taken only once or twice rather than three to five times a day, the less frequent administration of PHOSPHOLINE IODIDE (echothiophate iodide) gives greater likelihood that the eyedrops will actually be taken. 3 Moreover, with bedtime—and occasionally morning —dosage sufficing to control most cases, the patient need not always carry the drug with him during his working hours/ helps prevent deterioration of vision "Because of the long duration of its action, it would seem that phospholine iodide could be used to maintain control throughout the night and, by providing uninterrupted therapy, prevent or delay the progression of the disease." 5 three concentrations provide flexibility of dosage PHOSPHOLINE IODIDE {echothiophate iodide) is available in three concentrations—0.06%, 0.125%, and 0.25%—that "permit individualized treatment without increasing the frequency of application, depending on the status and response of the case."* concomitant therapy Concomitant administration with PHOSPHOLINE IODIDE (echothiophate iodide) of sympathomi- metics or carbonic anhydrase inhibitors Is permissible as indicated. Indications: Chronic simple (open-angle) glaucoma, secondary glaucomas, especially aphakic, chronic angle closure glaucoma after peripheral iridectomy. Warning: Medication should be temporarily discontinued if (otherwise unexplainable) persistent diarrhea, profuse sweating, or muscle weakness should occur. Antidote: Atropine, 2 mg, parenterally; artificial respiration, if needed. Precautions and Side Effects: Browache, dimness of vision, or ciliary and conjunctiva! injection may occur during initial therapy but will usually disappear after 5 to 10 days of continuous treatment. Iris cysts may occur in children and occasionally in adults. They usually do not interfere with continuation of treatment and will regress on reduction of dosage. Retinal detachment has occurred, and PHOSPHOLINE IODIDE (echothiophate iodide) should be used with extreme caution, if at all, where there is a history of this disorder. It may cause or activate acute iritis, and slit lamp examination before initial therapy and several times during the first week of therapy has been recommended. If patient is receiving other anticholinesterases systemically, the possibility of drug interaction must be considered. Prior to surgery, PHOSPHOLINE IODIDE (echothiophate iodide) is not generally recommended in angle closure glaucoma, but it may, nevertheless, be used, under close supervision, in the noncongestive phase if the tension is elevated and operation is refused or contraindicated. Supplied: 3.0 mg. package for 0.06% solution; 6.25 mg. package for 0.125% solution; 12.5 mg. package for 0.25% solution. Each solution also contains mannitol, chlorobutanol (chloral derivative), boric acid, and sodium phosphate. References: 1. Lawlor, R. C, and Lee, Pei-Fei: Am. J. Ophth. 49:808 (Apr.) 1960. 2. Gray, L. F., and Robinson, J. P.: Ibid 49:1162 (May) 1960. 3. Coyle, J. T., Weiner, A., Frank, P., and Leonard, A.: Ibid 52:867 (Dec.) 1961. 4. Hirsch-Hoffman, A. M.: Ophthalmologies 247:96 (Dec.) 1964. 5. Klayman, J., and Taffet, S.: Am. J. Ophth. 55:1233 (June) 1963. The Ophthalmos Division AYERST LABORATORIES New York, N.Y. 10017 • Montreal, Canada
Change language